ADMA Biologics Surges to 360th in Daily Rankings with $29.1 Million Turnover Despite Stock Price Drop

On May 8, 2025, ADMA Biologics (ADMA) experienced a significant increase in trading volume, with a turnover of $29.1 million, marking an 189.48% rise from the previous day. This surge placed ADMA at the 360th position in the daily stock market rankings. However, despite the high trading volume, ADMA's stock price fell by 10.21%.

ADMA Biologics reported a 40% year-over-year increase in total revenues for the first quarter of 2025, reaching $114.8 million. The company's adjusted earnings per share stood at 14 cents, with sales amounting to $114.8 million. Although earnings and sales missed analysts' expectations by a small margin, the company's performance still showed substantial growth compared to the previous year.

ADMA's stock decline was attributed to slightly missing Street's first-quarter expectations. The company's earnings missed expectations by a penny, and sales fell short of analysts' projections by $1.6 million. Despite this, analysts remained optimistic about ADMA's prospects. Mizuho Securities analyst Anthony Petrone raised his price target for ADMA stock to $35 from $32, citing strong sales growth and the company's new manufacturing process that is expected to boost immunoglobulin production by 20%.

ADMA also raised its sales outlook for 2025 and 2026, projecting $500 million and $625 million in sales, respectively. This guidance raise is based on organic growth, as the recently secured FDA clearance for immunoglobulin yield enhancement is not yet fully implemented. The company's strong financial performance and positive outlook have led to increased confidence from analysts, with Raymond James and Cantor Fitzgerald also raising their price targets for ADMA stock.